Novartis Pharmaceuticals Corp. March 19 announced that once-daily Arcapta Neohaler (indacaterol inhalation powder) now is available in the United States.
Arcapta Neohaler is indicated for the long-term maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated for the treatment of asthma. Based in East Hanover, N.J., Novartis Pharmaceuticals is an affiliate of Novartis AG, which is headquartered in Basel, Switzerland.
FDA approved the drug in July 2011 (9 PLIR 863, 7/8/11).
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.